Methods of preparing genetically engineered cells that produce insulin in response to glucose

• US 5,792,656 A
• Filed: 05/26/1995
• Issued: 08/11/1998
• Est. Priority Date: 06/03/1991
• Status: Expired due to Fees

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Newgard, Christopher B.
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): Gucker, Stephen
• Application Number:
  US08/452,346
• Time in Patent Office: 1,173 Days
• Field of Search: 435/172.1-172.3, 435/325, 435/382, 435/395, 935/52
• US Class Current: 435/325
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/62 Insulins
• CPC Class Codes: G01N 2800/042 Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
• CPC Class Codes: G01N 33/50 Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
• CPC Class Codes: G01N 33/567 utilising isolate of tissue or organ as binding agent
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
• CPC Class Codes: Y10S 977/914 Protein engineering
• CPC Class Codes: Y10S 977/918 Immunological
• CPC Class Codes: Y10S 977/927 Diagnostic contrast agent

Abstract

The present disclosure relates to the application of genetic engineering to provide artificial β cells, i.e. cells which can secrete insulin in response to glucose. This is achieved preferably through the introduction of one or more genes selected from the insulin gene, glucokinase gene, and glucose transporter gene, so as to provide an engineered cell having all three of these genes in a biologically functional and responsive configuration. Assays for detecting the presence of diabetes-associated antibodies in biological samples using these and other engineered cells expressing diabetes-associated epitopes are described. Also disclosed are methods for the large-scale production of insulin by perfusing artificial β cells, grown in liquid culture, with glucose-containing buffers.

Claims

1. A method for preparing engineered cells having glucose-responsive insulin secretory capability, comprising the steps of:

(a) selecting starting cells that are capable of secreting insulin and that express a glucokinase gene to produce a functional glucokinase (hexokinase IV) protein;

(b) introducing into the cells a recombinant gene encoding a GLUT-2 glucose transporter protein; and

(c) selecting cells that express the recombinant gene to produce a functional GLUT-2 glucose transporter protein.

2. The method of claim 1, wherein the starting cells of step (a) are prepared by selecting starting cells that express a glucokinase gene and that are capable of forming secretory granules, introducing into the starting cells a recombinant insulin gene, and selecting cells having the ability to secrete insulin.

3. The method of claim 2, wherein the starting cells are endocrine cells.

4. The method of claim 3, wherein the starting cells are pituitary or thyroid cells.

5. The method of claim 3, wherein the starting cells are beta cells.

6. The method of claim 1, wherein the starting cells of step (a) are prepared by introducing into the starting cells a recombinant glucokinase gene, and wherein cells that express said glucokinase gene to produce a functional glucokinase protein are selected.

7. The method of claim 1, further comprising engineering the cells of step (a) or (c) of claim 1 to reduce their ability to produce active hexokinase I.

8. The method of claim 1, further comprising encapsulating the selected cells of step (c) of claim 1 with a biocompatible coating, or placing said cells into selectively permeable membrane in a protective housing.

15. The method of claim 1, wherein said recombinant gene encodes the rat islet GLUT-2 glucose transporter protein.

16. The method of claim 2, wherein the starting cells are AtT-20 cells.

17. The method of claim 2, wherein the starting cells are GH-1 or GH-3 cells.

18. The method of claim 2, wherein the starting cells are β

TC, RIN or HIT cells.

19. The method of claim 6, wherein said glucokinase gene is an islet isoform glucokinase gene.

23. The method of claim 1, wherein the cells secrete human insulin.

24. The method of claim 1, wherein the recombinant gene of step (b) is a cDNA.

25. The method of claim 7, wherein the hexokinase I activity is reduced by using an antisense RNA molecule that is complementary to and capable of binding to RNA transcripts of a hexokinase gene.

26. The method of claim 7, wherein the hexokinase I activity is reduced through the application of a positive/negative selection protocol.

9. A method for preparing engineered cells having glucose-responsive insulin secretory capability, comprising the steps of:

(a) selecting starting cells that are capable of forming secretory granules;

(b) introducing into the starting cells one or more recombinant genes selected from the group consisting of a GLUT-2 glucose transporter gene, a glucokinase (hexokinase IV) gene, and an insulin gene;

such that the cells comprise a competent GLUT-2 glucose transporter gene, glucokinase gene and insulin gene, wherein at least one of said genes is a recombinantly introduced gene; and

(c) selecting cells having glucose-responsive insulin secretory capability.

10. The method of claim 9, wherein the starting cells are endocrine cells.

11. The method of claim 10, wherein the starting cells are pituitary or thyroid cells.

12. The method of claim 9, wherein the starting cells are beta cells.

13. The method of claim 9, further comprising engineering the cells of step (a) or (c) of claim 9 to reduce their ability to produce active hexokinase I.

14. The method of claim 9, further comprising encapsulating the selected cells of step (c) of claim 9 with a biocompatible coating, or placing said cells into selectively permeable membrane in a protective housing.

20. The method of claim 9, wherein the starting cells are AtT-20 cells.

21. The method of claim 9, wherein the starting cells are GH-1 or GH-3 cells.

22. The method of claim 9, wherein the starting cells are β

TC, RIN or HIT cells.

27. The method of claim 9, wherein the starting cells comprise a human insulin gene.

28. The method of claim 9, wherein the starting cells are prepared by introducing into the starting cells at least a recombinant GLUT-2 glucose transporter gene.

29. The method of claim 28, wherein said recombinant GLUT-2 glucose transporter gene encodes an islet GLUT-2 glucose transporter protein.

30. The method of claim 9, wherein the starting cells are prepared by introducing into the starting cells at least a recombinant glucokinase gene.

31. The method of claim 30, wherein said recombinant glucokinase gene is an islet isoform glucokinase gene.

32. The method of claim 9, wherein the starting cells are prepared by introducing into the starting cells at least a recombinant insulin gene.

33. The method of claim 9, wherein at least one of the recombinant gene or genes of step (b) is a cDNA.

34. The method of claim 13, wherein the hexokinase I activity is reduced by using an antisense RNA molecule that is complementary to and capable of binding to RNA transcripts of a hexokinase gene.

35. The method of claim 13, wherein the hexokinase I activity is reduced through the application of a positive/negative selection protocol.

36. A method for preparing engineered cells having glucose-responsive insulin secretory capability, comprising the steps of:

(a) selecting starting cells that are capable of secreting insulin and that express a GLUT-2 glucose transporter gene to produce a functional GLUT-2 glucose transporter protein;

(b) introducing into the cells a recombinant glucokinase (hexokinase IV) gene; and

(c) selecting cells that express the recombinant glucokinase gene to produce a functional glucokinase protein.

37. The method of claim 36, wherein the cells secrete human insulin.

38. The method of claim 36, wherein the starting cells of step (a) are prepared by selecting starting cells that express a GLUT-2 glucose transporter gene and that are capable of forming secretory granules, introducing into the starting cells a recombinant insulin gene, and selecting cells having the ability to secrete insulin.

39. The method of claim 36, wherein the starting cells of step (a) are prepared by introducing into the starting cells a recombinant GLUT-2 glucose transporter gene and wherein cells that express said GLUT-2 glucose transporter gene to produce a functional GLUT-2 glucose transporter protein are selected.

40. The method of claim 38, wherein the starting cells are endocrine cells.

41. The method of claim 38, wherein the starting cells are pituitary or thyroid cells.

42. The method of claim 38, wherein the starting cells are beta cells.

43. The method of claim 38, wherein the starting cells are AtT-20 cells.

44. The method of claim 38, wherein the starting cells are GH-1 or GH-3 cells.

45. The method of claim 38, wherein the starting cells are β

TC, RIN or HIT cells.

46. The method of claim 36, wherein the recombinant gene of step (b) is a cDNA.

47. The method of claim 36, further comprising engineering the cells of step (a) or (c) of claim 36 to reduce their ability to produce active hexokinase I.

48. The method of claim 47, wherein the hexokinase I activity is reduced by using an antisense RNA molecule that is complementary to and capable of binding to RNA transcripts of a hexokinase gene.

49. The method of claim 47, wherein the hexokinase I activity is reduced through the application of a positive/negative selection protocol.

50. The method of claim 36, further comprising encapsulating the selected cells of step (c) of claim 36, with a biocompatible coating, or placing said cells into selectively permeable membrane in a protective housing.